The Analyst Landscape: 9 Takes On BrightSpring Health
Portfolio Pulse from Benzinga Insights
BrightSpring Health (NASDAQ:BTSG) received mixed analyst ratings with 9 analysts offering their perspectives in the past three months. The average 12-month price target is $17.28, down 33.54% from the previous $26.00. Analysts' actions include lowering and announcing new ratings, with price targets ranging from $11.50 to $26.00. BrightSpring Health's financial performance shows a 13.88% revenue growth but struggles with profitability and debt management, having a net margin of -5.79% and a debt-to-equity ratio of 5.98.
March 04, 2024 | 3:00 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
BrightSpring Health received mixed analyst ratings, with a significant drop in the average price target to $17.28 from $26.00. The company shows strong revenue growth but faces challenges in profitability and debt management.
The mixed analyst ratings and the significant drop in the average price target could lead to short-term uncertainty in BTSG's stock price. However, the strong revenue growth may provide some positive sentiment. The concerns over profitability and high debt levels could dampen investor enthusiasm, making the short-term impact neutral as investors weigh these factors.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100